The Relationship between the Global Burden of Influenza from 2017-2019 and COVID-19
===================================================================================

* Stefan David Baral
* Katherine B. Rucinski
* Jean Olivier Twahirwa Rwema
* Amrita Rao
* Neia Prata Menezes
* Daouda Diouf
* Adeeba Kamarulzaman
* Nancy Phaswana-Mafuya
* Sharmistha Mishra

## Abstract

**Background** SARS-CoV-2 and Influenza are lipid-enveloped viruses with differential morbidity and mortality but shared modes of transmission. We assessed whether historical patterns of regional influenza burden are reflected in the observed heterogeneity in COVID-19 cases across and within regions of the world.

**Methods** Weekly surveillance data reported in FluNet from January 2017–December 2019 for influenza and World Health Organization for COVID-19 (to May 31, 2020) across the seven World Bank regions were used to assess the total and annual number of influenza and COVID-19 cases per country, within and across all regions, to generate comparative descending ranks from highest to lowest burden of disease.

**Results** Across and within regions, rankings of influenza and COVID-19 were relatively consistent. Europe and Central Asia and North America ranked first and second for COVID-19 and second and first for influenza, respectively. East Asia and the Pacific traditionally ranked higher for influenza but to date, has been less affected by COVID-19. Between regions, Sub-Saharan Africa ranked amongst the least affected by both influenza and COVID-19.

**Conclusion** Consistency in distribution of the burden of COVID-19 and influenza suggest shared individual, structural, and environmental determinants of transmission. Regions with discrepancies between influenza and COVID-19 burden may provide further insight into the potential impact of non-pharmacologic interventions and intersections with environmental conditions. Ultimately, forecasting trends and informing interventions for novel respiratory pathogens like COVID-19 should leverage patterns in the relative burden of past respiratory pathogens and the relative impact of non-pharmacologic intervention strategies as prior information.

**Funding** None

## Introduction

The COVID-19 pandemic has affected each region of the world differently1. As of June, 2020, Europe and the Americas regions have registered the highest numbers of COVID-19 cases and deaths while South-East Asia, Sub-Saharan Africa, and the Western Pacific have experienced comparatively milder epidemics1. Heterogeneity in COVID-19 burden has also been observed within cities, across cities, and across regions within a country2,3. This heterogeneity likely stem from differences in underlying population structure with respect to age distribution, population and housing density, access to health care, burden of comorbidities, socio-economic and structural barriers to engagement in health, and the breadth and intensity of public health interventions. Furthermore, there remains active investigation into the heterogeneity of effects of both COVID-19 and the associated response on potential syndemics including infectious diseases such as HIV and tuberculosis and non-communicable conditions including mental health, reproductive health, and non-communicable diseases.

Similar to SARS-CoV-2, influenza is a lipid-enveloped respiratory virus but with a more established evidence base for both effective non-pharmacologic intervention strategies and transmission dynamics4-6. Importantly, influenza is associated with a shorter incubation period and with lower mortality than the currently estimated SARS-CoV-2 infection case fatality rate7,8. The relative risks of indoor vs. outdoor transmission, risks for contact, droplet-based, and aerosolization-mediated transmission are better established for influenza9-11. Influenza seasonality and spatial distribution are not fully understood but likely reflect individual, population, and environmental determinants12. Moreover, the annual burden and associated mortality secondary to pandemic and non-pandemic seasonal influenza strains vary significantly. The 2009 H1N1 pandemic was estimated to cause over 60 million cases in the United States, but resulted in higher mortality among youth but fewer deaths overall as older people were more likely to be immune13. In 2017, there were an estimated 45 million cases of mostly H3N2 and Influenza B in the United States but associated with higher mortality particularly among older adults given limited pre-existing immunity and limited vaccine effectiveness14. Environmental factors have been shown to explain in part the differences in influenza seasonality between temperate regions where cases peak during winter months, while tropical regions may have multiple peaks or intermittent influenza activity15,16. However, even within specific regions, some countries show influenza transmission patterns that are distinct from regional trends17,18.

There have been early reports suggesting shared determinants of infection between influenza and SARS-CoV-2. In the United States, there is evidence of higher COVID-19 incidence, morbidity and mortality among African American communities secondary to underlying inequities including structural racism19. These racial disparities were also observed during the 2009 H1N1 influenza pandemic with similar drivers including higher risk of exposure due to inability to social distance, higher burden of comorbidities and limited access to health care among African American and other racialized communities20-22. Similarly, the early trajectories of COVID-19 and 2009 H1N1 have been noted in South Africa23.

When this novel coronavirus emerged in early 2020, regional and national forecasting exercises drew on emerging data on the trajectory of detected cases of COVID-19 in the epicenters of China and Italy to translate their reproductive rates into best- and worst-case scenarios for local populations. That is, despite early comparison of the average mortality of influenza and SARS-CoV-2, there has not been a systematic evaluation of whether historical distributions in influenza burden are relevant in the prediction of the burden and distribution of SARS-CoV-2 infection. In this study, we comprehensively investigated global influenza transmission patterns from 2017 onwards to assess shared trends with the epidemiology of COVID-19.

## Methods

### Data abstraction and assessment of eligibility

#### Influenza

We used publicly available data to characterize temporal patterns of influenza across seven regions between 2017 and 2019. Organization of countries into regions was based on World Bank classifications, namely: East Asia and the Pacific, Europe and Central Asia, Latin America and the Caribbean, Middle East and North Africa, North America, South Asia, and sub-Saharan Africa. Within each region, we assessed country-specific weekly reported cases of influenza, including both Influenza A and B, from 1 January 2017 to 31 December 2019. Data were abstracted from FluNet, a global web-based tool developed by the World Health Organization for influenza virological surveillance, which captures weekly laboratory confirmed influenza cases. FluNet aggregates data from the National Influenza Centres of the Global Influenza Surveillance and Response System and other national influenza reference laboratories. Since more temperate zones in the Northern and Southern Hemispheres have generally opposing seasonal influenza trends, we report influenza case counts by calendar year from January 1 to December 31; which also facilitates comparisons with COVID-19. Finally, influenza case counts for the calendar year of 2020 were excluded given that public health measures focused on COVID-19 prevention and mitigation likely significantly decreased seasonal influenza cases for this time period24.

We assessed patterns of missing data for each country and by year to determine eligibility for inclusion in analyses. For each year, countries where ≥90% of available weekly case reports were complete (assessed as the total number of non-missing records over the total number of all included weeks for that year) were included in analyses. For countries where data were <90% complete, we made the following determination: Countries where data missingness appeared to follow a seasonal pattern (e.g, data were missing only for weeks outside of the known influenza season, likely reflecting country-specific seasonal influenza reporting guidelines) were retained in analyses. Countries where weekly case counts were <90% complete and did not appear to follow a seasonal pattern, were denoted as missing.

### COVID-19

We abstracted the daily number of COVID-19 cases reported between 1 January 2020 and 31 May 2020 for all countries and corresponding World Bank regions using data from the World Health Organization Coronavirus Situation Report. As we are in the first year of COVID-19, it was not possible to assess missingness of data similar to the methods used for influenza.

### Regional rankings of Influenza and COVID-19 burden

#### Influenza

We assessed the overall burden of influenza for all included countries across and within each region. To do so, we summed the absolute number of influenza cases for each region, country and year (January 1 to December 31 of each year) given the temporal variability in influenza seasons around the world. Regions were ranked in descending order from highest to lowest number of absolute cases for 2017, 2018, and 2019. Countries were similarly ranked within regions, and overall, for each year. For each region, we plotted weekly influenza cases for the five highest ranked countries on a linear scale. Plots were visually inspected to assess for presence of temporal patterns within and across regions. We focused on case counts rather than per-capita rates given the concentration of both burden and testing generally in urban centers. Thus, using the entire country as a denominator inherently masks heterogeneity in the burden of infection within that country. Moreover, the relative proportion of the population residing in urban centers varies by country and by region, further challenging comparisons using per-capita rates. We further included analyses with ranks for influenza also created based on the total number of influenza cases reported for the first 20 weeks of each year (January 1 to May 31), as well as the total number of annual cases per capita of the country’s population assuming stable population sizes from 2017-2019.

#### COVID-19

We assessed, and similarly ranked, in descending order, cumulative cases of COVID-19 as reported through 31 May, for each region. Countries were also ranked within their respective regions and overall.

#### Comparison of between and within-regional burden of Influenza and COVID-19

We used rankings derived from COVID-19 case counts to anchor cross-pathogen comparisons. The seven World Bank regions were ranked in descending order by total COVID-19 burden. We utilized heat maps to visually represent differences in rank order of regions across influenza years. We employed similar methods to compare rank order of countries within regions and overall. By region, we used heat maps to compare the rank order of the top 15 countries with highest reported COVID-19 burden, to their order in rankings of total influenza cases in 2017, 2018, and 2019, separately. We described similarities or differences across and within all regions.

## Results

Influenza cases were assessed for 171 countries. For each year, more than half (ranging from 55.6%-56.7%) of all countries reported ≥90% complete data (**Supplemental Table 1**). The proportion of countries where data were <90% complete, but followed a pattern of seasonal missingness were also included in influenza analyses, ranged from 22.8% in 2017 to 24.0% in 2019. Differences in data completion and patterns of missingness were evident across all regions. The overall influenza burden between 2017 and 2019 varied by region and by countries within all seven identified regions (**Table 1**). Regions with the highest absolute burden of influenza included North America (903,554 cases), Europe and Central Asia (599,820 cases), and East Asia and the Pacific (389,657 cases). Countries with the highest proportion of regional influenza cases were as follows: East Asia and the Pacific (China; 77.5%); Europe and Central Asia (the United Kingdom; 17.7%), Latin America and the Caribbean (Mexico, 20.2%), Middle East and North Africa (Qatar, 40.5%), North America (the United States, 82.9%), South Asia (India, 46.6%), and Sub-Saharan Africa (South Africa, 18.7%).

View this table:
[TABLE 1.](http://medrxiv.org/content/early/2020/06/20/2020.06.18.20134346/T1)

TABLE 1. 
Influenza cases for top 15 countries by World Bank region, overall and by year from January 1 2017 to December 31 2019*

*Rankings exclude countries with missing influenza data

Seasonal variation in influenza cases was observed within nearly all regions. Seasonal trends were most pronounced for the Middle East and North Africa, North America, Europe, and East Asia and the Pacific (**Figure 1**). Seasonal trends were less evident for Latin America and the Caribbean, South Asia, and sub-Saharan Africa, where no specific trends in the timing and absolute peak of influenza cases were observed. Across regions, countries with the highest overall burden of influenza from 2017 to 2019, included the United States (749,472 cases), China (302,126 cases), Canada (154,082 cases), the United Kingdom (106,087 cases), and Norway (71,727 cases).

![FIGURE 1.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2020/06/20/2020.06.18.20134346/F1.medium.gif)

[FIGURE 1.](http://medrxiv.org/content/early/2020/06/20/2020.06.18.20134346/F1)

FIGURE 1. 
Weekly trends in total influenza cases between January 1 2017 and December 31 2019 extracted from FluNet. **A**=Middle East and North Africa; **B**=Latin America and the Caribbean; **C**=South Asia; **D**=Sub-Saharan Africa; **E**=North America; **F**=East Asia Pacific; **G**=Europe and Central Asia

Regions with the highest absolute burden of COVID-19 included Europe and Central Asia (2,116,249 cases), North America (1,890,586 cases), and Latin America and Caribbean (852,368 cases) (**Table 2**). Within each region, countries with the highest proportion of COVID-19 regional cases were as follows: East Asia and the Pacific (China; 39.8%); Europe and Central Asia (Russia; 19.2%), Latin America and the Caribbean (Brazil, 49.6%), Middle East and North Africa (Iran, 33.8%), North America (the United States, 95.0%), South Asia (India, 57.1%), and Sub-Saharan Africa (South Africa, 32.3%) (**Table 2)** Specific countries with the highest overall burden of COVID-19 cases as of May 31, 2020 included the United States (1,716,078 cases), Brazil (465,166 cases), Russia (405,843 cases), the United Kingdom (272,830 cases), and Spain (239,600 cases) (**Table 2)**.

View this table:
[TABLE 2.](http://medrxiv.org/content/early/2020/06/20/2020.06.18.20134346/T2)

TABLE 2. 
COVID-19 cases for top 15 countries by World Bank region, overall and by year from January 1 2020 to May 31 2020

Regional rankings of total COVID-19 and influenza burden were relatively consistent. For instance, Europe and Central Asia ranked first in COVID-19 and consistently ranked second in influenza burden from 2017-2019, while North America ranked second in COVID-19 and consistently ranked first in influenza burden (**Figure 2**). South Asia which ranked fifth in COVID-19 burden, consistently ranked sixth in influenza burden across all three influenza years. Sub-Saharan Africa ranked lowest both in the burden of COVID-19 and influenza. Latin America and Caribbean, and Middle East and North Africa maintained their position in the middle for both rankings. The exception was East Asia and Pacific that ranked sixth in COVID-19 burden despite a consistent ranking of third for influenza burden (**Figure 2**).

![FIGURE 2.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2020/06/20/2020.06.18.20134346/F2.medium.gif)

[FIGURE 2.](http://medrxiv.org/content/early/2020/06/20/2020.06.18.20134346/F2)

FIGURE 2. 
Rank order of seven World Bank regions by COVID-19 burden from January 1 to May 31 2020 and influenza cases from January 1 2017 to December 31 2019

When we compared rankings of the top 15 countries with the highest COVID-19 burden from January 1 to May 31 2020 to those with highest influenza burdens, rankings remained partly conserved across and within all regions. Within regions, countries with the highest COVID-19 burden were similarly ranked as having a high burden of influenza from 2017 to 2019. For instance, South Africa, China, India, the United States, and Brazil had the highest rankings of COVID-19 in their respective regions and similarly within-region higher ranking for influenza burden from 2017-2019. Russia and United Kingdom had the top two rankings in Europe and Central Asia. The United Kingdom has ranked first in influenza from 2017-2019 while Russia ranked always in top five in influenza burden except in 2018 where it ranked seventh. Overall, in all regions, countries that ranked low in influenza burden generally ranked lower in COVID-19 burden as well (**Figure 3**). Influenza rankings restricted to the total number of influenza cases reported for the first 20 weeks of each year (January 1 – May 31), as well as the total number of annual cases per capita, are reported in **Supplemental Figures 2 and 3**.

![](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2020/06/20/2020.06.18.20134346/F3/graphic-9.medium.gif)

[](http://medrxiv.org/content/early/2020/06/20/2020.06.18.20134346/F3/graphic-9)

![](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2020/06/20/2020.06.18.20134346/F3/graphic-10.medium.gif)

[](http://medrxiv.org/content/early/2020/06/20/2020.06.18.20134346/F3/graphic-10)

![](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2020/06/20/2020.06.18.20134346/F3/graphic-11.medium.gif)

[](http://medrxiv.org/content/early/2020/06/20/2020.06.18.20134346/F3/graphic-11)

FIGURE 3. 
Rank order of top 15 countries by COVID-19 burden from January 1 to May 31 2020 and influenza cases within seven World Bank regions, from January 1 2017 to December 31 2019

## Discussion

In this study, we found ecological consistency between the burden of influenza from 2017-2019 and the recorded number of COVID-19 cases to date. Specifically, North America, Europe and Central Asia generally reported the highest numbers of influenza cases per year and have also had the highest the highest burden of COVID-19. Outside of East Asia and the Pacific, regions with lower levels of COVID-19 generally ranked lower in influenza burden using historical data. East Asia and the Pacific ranked third in 2017-2019 for influenza burden but is ranked second last above Sub-Saharan Africa for COVID-19. Within regions, there was also general consistency between countries that generally ranked higher in historical influenza cases and those with higher COVID-19 case counts. The ecological consistency in the burden of COVID-19 and the recent burden of influenza is suggestive of likely shared individual, structural, and environmental determinants of infection.

Outside of public health interventions, there is generally less consensus on the determinants that potentiate or inhibit COVID-19 transmission. However, given decades of study, there is more information available on the individual, population-level, and environmental determinants of influenza. At the individual level, underlying immunity is related to previous exposure to similar strains and vaccine uptake and effectiveness. Effectiveness of vaccines depends on circulating influenza strains i.e pandemic and non-pandemic, or seasonal; secondary to antigenic drift and shift of influenza viruses. Population-level characteristics include vaccine coverage and shield immunity, population density, social norms, and health care infrastructure. Finally, environmental factors affecting influenza include temperature, air pollution, and humidity25,26. Given how rapidly COVID-19 has emerged, conclusions of different studies exploring the role of environmental conditions have differed significantly. One study found no associations between latitude and temperature with COVID-19 epidemic growth using a two-week exposure period in March across 144 geopolitical areas27. However, a “living” review leveraging data from December, 2019 onwards from nearly 4000 locations across the world showed significant differences in COVID-19 burden associated with temperature, humidity, pollution, and other environmental factors28. Collectively, these studies suggest the potential for at least some seasonal variation secondary to changes in environmental conditions in the transmission of SARS-CoV-2 similar to other respiratory pathogens, including influenza and other seasonal coronaviruses29-32.

Influenza seasonality is more pronounced in more temperate areas of the Northern and Southern hemispheres consistent with opposing fall and winter seasons. A recent assessment of the seasonality of infectious pathogens included individual-level determinants. such as growing immunity throughout an influenza season secondary to vaccination or exposure, that results in achieving effective levels of shield immunity limiting transmission33. There has been some study of existing immunity to COVID-19 mediated via cross-reactivity with other coronaviruses 33,34. However, lesser population-wide immunity could mean sustained transmission even during times with less transmission of other respiratory pathogens. Influenza seasonality may also be secondary to population-level changes including potentially higher crowding in colder weathers, increased use of respite care and housing, people returning to work and school, and increased use of transit services that may collectively facilitate transmission. Environmental conditions may further affect individual susceptibility to infection as well as contact or respiratory droplet transmission patterns. The recent increases in COVID-19 in late May and early June in some areas of the Southern hemisphere including countries across South America are consistent with the timing of the traditional influenza season35. Moreover, in South Africa, epicenters of COVID-19 appear to be similar to areas with increased influenza transmission36,37. In the less temperate areas of Sub-Saharan Africa and Southeast Asia, influenza burden appears to be generally lower. While there is likely a relationship between testing infrastructure and influenza reporting, the consistency in the COVID-19 and influenza burden among countries within each region was notable. East Asia and the Pacific is an exception here with generally higher burdens of influenza and more limited COVID-19 cases. Given that COVID-19 emerged in this region, non-pharmacologic interventions widely implemented and shown to have affected both COVID-19 and influenza burden may explain this finding24. In addition, while influenza is endemic in several countries, rapidly decreasing introduction of COVID-19 through the closure of borders likely played a critical role especially in settings experiencing traditional influenza season.

A hallmark of COVID-19 has been the role of social determinants of health with socioeconomic status, living conditions, access to health care, and underlying comorbidities being consistent predictors of COVID-19 incidence and mortality around the world38,39. Moreover, structural racism has been documented in several settings including the United States, United Kingdom, and Canada, but likely relevant in many more settings not reporting on racial identity of those affected40,41. Notably, similar disparities were observed in the 2009 H1N1 pandemic in the United States though there has been limited documentation of socioeconomic disparities of influenza in most settings20,42. While disparities are well documented for other infectious diseases such as HIV, these disparities evolve across cycles of transmission spanning years. Given how rapidly disparities emerged with COVID-19, interventions to address disparities may be observable over shorter time horizons and provide insight into effective interventions to address pervasive social health inequities. Secondary to intersections of differential access to health care and medical mistrust, the development of a generally effective vaccine has not mitigated disparities43-45. Leveraging frameworks focused on optimizing implementation of influenza vaccination strategies including increased equity will be critical in informing SARS-CoV-2 vaccines when available46,47. COVID-19 is also rapidly increasing our understanding of post-viral morbidities including cardiovascular complications48. While post-viral complications have been described for other viruses, the mechanisms of consequences may be elucidated based on the research into COVID-19 broadening the potential impact of these studies49-53.

This study has several limitations. Risk of ecological fallacy is relevant where individuals in generally lower ranking regions or countries may have high risks of acquisition and transmission secondary to micro-epidemics, including in those in congregate living settings, refugee and migrant work camps, long term care facilities, homeless shelters, and prisons. Missingness in data aggregated by FluNet is another limitation. We assumed that countries where influenza data was missing in a seasonal pattern was a reflection of very few case counts and/or reduced reporting outside of the typical influenza season, and indeed seasonal “missingness” was most apparent for countries in the European region, where the influenza season has been well documented. However, by excluding countries with > 10% data missingness that did not follow a seasonal influenza pattern, several sub-Saharan African countries (e.g. Sudan) were not included in the comparison of rankings despite high COVID-19 and influenza burden. Absolute influenza and COVID-19 case counts were reported, rather than positivity rates given that testing eligibility and subsequent testing rates may have varied dramatically within and across countries. Biases present in interpreting positivity rates, such as availability of infrastructure to implement broad testing strategies, may be reflected in total number of case counts, across both influenza and COVID-19.

The results presented here suggest that the distribution in the global burden of COVID-19 reflects that of influenza. This ecological overlap suggests that the underlying dynamics of transmission of influenza and COVID-19 are similar as they relate to spatial, seasonal, population structure and the disparities that lead to disproportionate vulnerabilities in various population groups. In considering the host-pathogen-environment framework commonly used for infectious diseases, emerging infections represent novel pathogens, but the populations and environment under which they emerge and spread are the same. Similarly, the similarities observed here suggest the potential utility of informing COVID-19 prevention and mitigation interventions with the vast data available characterizing critical issues including the relative risks of indoor vs. outdoor transmission, risks of aerosolization for influenza, and even optimal delivery of vaccines and chemoprophylaxis and treatment strategies when developed. Ultimately, regional and national public health systems preparing and responding to the current and future waves of COVID-19 may benefit from evaluating the relative burden of past respiratory pathogens and the impact of non-pharmacologic intervention strategies as prior information when forecasting and implementing interventions.

## Data Availability

All data reported in this manuscript are publicly available. Influenza data were abstracted from FluNet, a global web-based tool developed by the World Health Organization for influenza virological surveillance, which captures weekly laboratory confirmed influenza cases. COVID-19 data through 31 May, 2020 were abstracted from the World Health Organization Coronavirus Situation Report.

[https://www.who.int/influenza/gisrs\_laboratory/flunet/en/](https://www.who.int/influenza/gisrs_laboratory/flunet/en/) 

[https://reliefweb.int/report/world/coronavirus-disease-covid-19-situation-report-132-31-may-2020](https://reliefweb.int/report/world/coronavirus-disease-covid-19-situation-report-132-31-may-2020) 

## Footnotes

*   **Email Addresses of Authors** Stefan Baral: sbaral{at}jhu.edu; Katherine Rucinski : rucinski{at}jhu.edu; Jean Olivier Twahirwa Rwema: jtwahir1{at}jhmi.edu; Amrita Rao: arao24{at}jhu.edu; Neia Prata Menezes : npratam1{at}jhmi.edu; Daouda Diouf: dioufda{at}endatiersmonde.org; Adeeba Kamarulzaman: adeeba{at}ummc.edu.my; Nancy Phaswana-Mafuya: phaswanamafuyanancy{at}gmail.com; Sharmistha Mishra: sharmistha.mishra{at}utoronto.ca

*   Received June 18, 2020.
*   Revision received June 18, 2020.
*   Accepted June 20, 2020.


*   © 2020, Posted by Cold Spring Harbor Laboratory

This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)

## References

1.  1.WHO. COVID-19 situation report - 133. World Health Organization; 2020 2020.
    
    

2.  2.Devlin H. Regional differences in Covid-19 transmission rate emerge in England. The Guardian. May 15, 2020, 2020.
    
    

3.  3.CDC. Geographic Differences in COVID-19 Cases, Deaths, and Incidence — United States, February 12–April 7, 2020. USA: CDC;2020.
    
    

4.  4.Ahmed F, Zviedrite N, Uzicanin A. Effectiveness of workplace social distancing measures in reducing influenza transmission: a systematic review. BMC Public Health. 2018;18(1):518.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/s12889-018-5446-1&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F06%2F20%2F2020.06.18.20134346.atom) 

5.  5.Long Y, Hu T, Liu L, et al. Effectiveness of N95 respirators versus surgical masks against influenza: A systematic review and meta-analysis. J Evid Based Med. 2020;13(2):93–101.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F06%2F20%2F2020.06.18.20134346.atom) 

6.  6.Feng S, Shen C, Xia N, Song W, Fan M, Cowling BJ. Rational use of face masks in the COVID-19 pandemic. Lancet Respir Med. 2020;8(5):434–436.
    
    

7.  7.Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DA. Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis. 2009;9(5):291–300.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S1473-3099(09)70069-6&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=19393959&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F06%2F20%2F2020.06.18.20134346.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000265805200017&link_type=ISI) 

8.  8.Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of mortality following COVID-19 infection. The Lancet Infectious Diseases.
    
    

9.  9.Yang W, Elankumaran S, Marr LC. Concentrations and size distributions of airborne influenza A viruses measured indoors at a health centre, a day-care centre and on aeroplanes. J R Soc Interface. 2011;8(61):1176–1184.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1098/rsif.2010.0686&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21300628&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F06%2F20%2F2020.06.18.20134346.atom) 

10. 10.Marr LC, Tang JW, Van Mullekom J, Lakdawala SS. Mechanistic insights into the effect of humidity on airborne influenza virus survival, transmission and incidence. J R Soc Interface. 2019;16(150):20180298.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1098/rsif.2018.0298&link_type=DOI) 

11. 11.Yang W, Marr LC. Dynamics of airborne influenza A viruses indoors and dependence on humidity. PLoS One. 2011;6(6):e21481.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0021481&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21731764&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F06%2F20%2F2020.06.18.20134346.atom) 

12. 12.Moriyama M, Hugentobler WJ, Iwasaki A. Seasonality of Respiratory Viral Infections. Annu Rev Virol. 2020.
    
    

13. 13.Hancock K, Veguilla V, Lu X, et al. Cross-Reactive Antibody Responses to the 2009 Pandemic H1N1 Influenza Virus. New England Journal of Medicine. 2009;361(20):1945–1952.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa0906453&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=19745214&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F06%2F20%2F2020.06.18.20134346.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000271660500008&link_type=ISI) 

14. 14.Allen JD, Ross TM. H3N2 influenza viruses in humans: Viral mechanisms, evolution, and evaluation. Hum Vaccin Immunother. 2018;14(8):1840–1847.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1080/21645515.2018.1462639:1-8&link_type=DOI) 

15. 15.Tamerius JD, Shaman J, Alonso WJ, et al. Environmental predictors of seasonal influenza epidemics across temperate and tropical climates. PLoS Pathog. 2013;9(3):e1003194.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.ppat.1003194&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=23505366&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F06%2F20%2F2020.06.18.20134346.atom) 

16. 16.Hirve S, Newman LP, Paget J, et al. Influenza Seasonality in the Tropics and Subtropics - When to Vaccinate? PLoS One. 2016;11(4):e0153003.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F06%2F20%2F2020.06.18.20134346.atom) 

17. 17.Saha S, Chadha M, Shu Y, Group of Asian Researchers on I. Divergent seasonal patterns of influenza types A and B across latitude gradient in Tropical Asia. Influenza Other Respir Viruses. 2016;10(3):176–184.
    
    

18. 18.Xu ZW, Li ZJ, Hu WB. Global dynamic spatiotemporal pattern of seasonal influenza since 2009 influenza pandemic. Infect Dis Poverty. 2020;9(1):2.
    
    

19. 19.Millett GA, Jones AT, Benkeser D, et al. Assessing Differential Impacts of COVID-19 on Black Communities. Ann Epidemiol. 2020.
    
    

20. 20.Quinn SC, Kumar S, Freimuth VS, Musa D, Casteneda-Angarita N, Kidwell K. Racial disparities in exposure, susceptibility, and access to health care in the US H1N1 influenza pandemic. Am J Public Health. 2011;101(2):285–293.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.2105/AJPH.2009.188029&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21164098&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F06%2F20%2F2020.06.18.20134346.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000286300600024&link_type=ISI) 

21. 21.Bibbins-Domingo K. This Time Must Be Different: Disparities During the COVID-19 Pandemic. Ann Intern Med. 2020.
    
    

22. 22.Kirby T. Evidence mounts on the disproportionate effect of COVID-19 on ethnic minorities. The Lancet Respiratory Medicine. 2020.
    
    

23. 23.Phaswana-Mafuya N, Shisana O, Gray G, et al. The utility of 2009 H1N1 pandemic data in understanding the transmission potential and estimating the burden of COVID-19 in South Africa to guide mitigation strategies. 2020.
    
    

24. 24.Cowling BJ, Ali ST, Ng TWY, et al. Impact assessment of non-pharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: an observational study. Lancet Public Health. 2020;5(5):e279–e288.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F06%2F20%2F2020.06.18.20134346.atom) 

25. 25.Lofgren E, Fefferman NH, Naumov YN, Gorski J, Naumova EN. Influenza seasonality: underlying causes and modeling theories. J Virol. 2007;81(11):5429–5436.
    
    [FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiRlVMTCI7czoxMToiam91cm5hbENvZGUiO3M6MzoianZpIjtzOjU6InJlc2lkIjtzOjEwOiI4MS8xMS81NDI5IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjAvMDYvMjAvMjAyMC4wNi4xOC4yMDEzNDM0Ni5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

26. 26.Lowen AC, Steel J. Roles of humidity and temperature in shaping influenza seasonality. J Virol. 2014;88(14):7692–7695.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoianZpIjtzOjU6InJlc2lkIjtzOjEwOiI4OC8xNC83NjkyIjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjAvMDYvMjAvMjAyMC4wNi4xOC4yMDEzNDM0Ni5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

27. 27.Juni P, Rothenbuhler M, Bobos P, et al. Impact of climate and public health interventions on the COVID-19 pandemic: A prospective cohort study. CMAJ. 2020.
    
    

28. 28. Ran Xu,  Hazhir Rahmandad,  Marichi Gupta, et al. The Modest Impact of Weather and Air Pollution on COVID-19 Transmission. preprint. 2020.
    
    

29. 29.Sajadi MM, Habibzadeh P, Vintzileos A, Shokouhi S, Miralles-Wilhelm F, Amoroso A. Temperature, Humidity, and Latitude Analysis to Estimate Potential Spread and Seasonality of Coronavirus Disease 2019 (COVID-19). JAMA Netw Open. 2020;3(6):e2011834.
    
    

30. 30.Causal empirical estimates suggest COVID-19 transmission rates are highly seasonal. 2020.
    
    

31. 31.Climate affects global patterns of COVID-19 early outbreak dynamics. 2020.
    
    

32. 32.Neher RA, Dyrdak R, Druelle V, Hodcroft EB, Albert J. Potential impact of seasonal forcing on a SARS-CoV-2 pandemic. Swiss Med Wkly. 2020;150:w20224.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.4414/smw.2020.20224&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32176808&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F06%2F20%2F2020.06.18.20134346.atom) 

33. 33.Cohen J. Why do dozens of diseases wax and wane with the seasons—and will COVID-19? In. Science Mag 2020.
    
    

34. 34.Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020.
    
    

35. 35.Collyns D. Peru’s coronavirus response was ‘right on time’ – so why isn’t it working? ([https://www.theguardian.com/global-development/2020/may/20/peru-coronavirus-lockdown-new-cases](https://www.theguardian.com/global-development/2020/may/20/peru-coronavirus-lockdown-new-cases)). Published 2020. Accessed.
    
    

36. 36.NICD. Weekly Respiratory Pathogens Surveillance Report - Week 23, 2020. South Africa: National Institute for Communicable Diseases;2020.
    
    

37. 37.NICD. National COVID-19 daily report - June 15, 2020. South Africa National Institute for Communicable Diseases 2020.
    
    

38. 38.Mishra S, Kwong JC, Chan AK, Baral SD. Understanding heterogeneity to inform the public health response to COVID-19 in Canada. CMAJ : Canadian Medical Association journal = journal de l’Association medicale canadienne. 2020.
    
    

39. 39.Okonkwo NE, Aguwa UT, Jang M, et al. COVID-19 and the US response: accelerating health inequities. BMJ Evid Based Med. 2020.
    
    

40. 40.Millett GA, Jones AT, Benkeser D, et al. Assessing Differential Impacts of COVID-19 on Black Communities. Annals of epidemiology. 2020.
    
    

41. 41.Yaya S, Yeboah H, Charles CH, Otu A, Labonte R. Ethnic and racial disparities in COVID-19-related deaths: counting the trees, hiding the forest. BMJ Glob Health. 2020;5(6).
    
    

42. 42.Weinman AL, Sullivan SG, Vijaykrishna D, et al. Epidemiological trends in notified influenza cases in Australia’s Northern Territory, 2007-2016. Influenza Other Respir Viruses. 2020.
    
    

43. 43.Hall LL, Xu L, Mahmud SM, Puckrein GA, Thommes EW, Chit A. A Map of Racial and Ethnic Disparities in Influenza Vaccine Uptake in the Medicare Fee-for-Service Program. Adv Ther. 2020;37(5):2224–2235.
    
    

44. 44.Loiacono MM, Mahmud SM, Chit A, et al. Patient and practice level factors associated with seasonal influenza vaccine uptake among at-risk adults in England, 2011 to 2016: An age-stratified retrospective cohort study. Vaccine X. 2020;4:100054.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jvacx.2020.100054&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32072152&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F06%2F20%2F2020.06.18.20134346.atom) 

45. 45.Akpalu Y, Sullivan SJ, Regan AK. Association between health insurance coverage and uptake of seasonal influenza vaccine in Brazos County, Texas. Vaccine. 2020;38(9):2132–2135.
    
    

46. 46.Wang L, Chen J, Marathe A. A Framework for Discovering Health Disparities among Cohorts in an Influenza Epidemic. World Wide Web. 2019;22(6):2997–3020.
    
    

47. 47.Webster F, Gidding H, Matthews V, Taylor R, Menzies R. What isn’t measured isn’t done - eight years with no progress in Aboriginal and Torres Strait Islander adult influenza and pneumococcal vaccination. Australian and New Zealand journal of public health. 2019;43(6):558–562.
    
    

48. 48.Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. Am J Emerg Med. 2020:S0735-6757(0720)30277-30271.
    
    

49. 49.Maggio MC, Cimaz R, Alaimo A, Comparato C, Di Lisi D, Corsello G. Kawasaki disease triggered by parvovirus infection: an atypical case report of two siblings. J Med Case Rep. 2019;13(1):104.
    
    

50. 50.Puttaraksa K, Pirttinen H, Karvonen K, Nykky J, Naides SJ, Gilbert L. Parvovirus B19V Nonstructural Protein NS1 Induces Double-Stranded Deoxyribonucleic Acid Autoantibodies and End-Organ Damage in Nonautoimmune Mice. The Journal of Infectious Diseases. 2018;219(9):1418–1429.
    
    

51. 51.Iglesias-Gamarra A, Restrepo JF, Matteson EL. Small-vessel vasculitis. Curr Rheumatol Rep. 2007;9(4):304–311.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=17688840&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F06%2F20%2F2020.06.18.20134346.atom) 

52. 52.Crudele GD, Amadasi A, Marasciuolo L, Rancati A, Gentile G, Zoja R. A case report of lethal post-viral lymphocytic myocarditis with exclusive location in the right ventricle. Leg Med (Tokyo). 2016;19:1-4.
    
    

53. 53.Smatti MK, Cyprian FS, Nasrallah GK, Al Thani AA, Almishal RO, Yassine HM. Viruses and Autoimmunity: A Review on the Potential Interaction and Molecular Mechanisms. Viruses. 2019;11(8):762.